CoChat

Revitalizing liver function in mice with liver failure through transplantation of 3D-bioprinted liver with expanded primary hepatocytes

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 3 of the 9 sources its claims cite were checked for support.

Abstract

This study outlines our strategy for constructing a 3D-bioprinted liver, using in vitro-expanded primary hepatocytes recognized for their safety and enhanced functional robustness as hepatic cell sources for bioartificial liver construction... Upon heterotopic transplantation into the mesentery of tyrosinemia or 90% hepatectomy mice, our 3D-bioprinted liver effectively restored lost liver functions...

Overview

CoChat Summary

TL;DR

This study built a 3D-bioprinted liver (“3DP-liver”) from in vitro–expanded primary mouse hepatocytes in a liver decellularized matrix/gelatin/sodium alginate bioink and showed that it can mature in vitro and restore liver function after heterotopic transplantation in mice. In Fah−/− tyrosinemia mice and 90% hepatectomized mice, transplantation improved biochemical liver injury markers and extended survival, and an added artificial blood vessel enabled biomolecule exchange and direct vascular connection in principle.

Key findings

  • Primary mouse hepatocytes were expanded for more than 25 generations, with a theoretical cell count exceeding 1 × 10^20; 96.9 ± 1.5% of analyzed eHep cells stained positive for albumin.
  • A 5% 3D-DLS gel (liver decellularized matrix + gelatin + sodium alginate) gave the best printing/biocompatibility performance; after 5 days of culture, 23.3 ± 2.4% of eHep cells were Ki67-positive, and cell survival was >99% at 3% and 5% gel concentrations.
  • The 3DP-liver showed mature liver functions in vitro, including higher expression of hepatic genes (Alb, Ttr, Trf, Ck18), induction of drug-metabolism genes, CYP1A2 activity, ICG uptake/release, glycogen storage, and ac-LDL uptake.
  • In Fah−/− mice, 3DP-liver transplantation reduced serum tyrosine and phenylalanine, lowered injury markers (ALT, AST, TBA, TBIL, DBIL, ALP), increased ALB, improved histology, and prolonged lifespan; in 90% hepatectomized mice, it also significantly extended survival.
  • With an artificial blood vessel, Cy7 and glucose diffused through the construct, and the authors report that a vascularized 3DP-liver could be directly connected to rat vessels without observed leakage in their setup.

Methods

  • Mouse hepatocytes were isolated from 6- to 8-week-old C57 mice, expanded in hepatocyte expansion medium, and combined with liver decellularized matrix, gelatin, and sodium alginate to make a 3D-DLS bioink for extrusion bioprinting.
  • The authors assessed rheology/mechanics, cell viability/proliferation, gene expression (qPCR, RNA-seq), and liver-specific functions in vitro, then transplanted 3DP-liver into the mesentery of mice for in vivo testing.
  • In vivo studies used C57BL/6NCrl mice and Fah−/− mice (with NTBC withdrawal) for therapeutic testing, plus a 90% hepatectomy mouse model; survival and serum liver biochemistry were analyzed with t tests/ANOVA.

Limitations

  • The authors explicitly note that the artificial blood vessel’s toughness was insufficient in rats, which can cause blood leakage because of active movement, so the vascular fixation/transplantation system needs further refinement.
  • The work is a proof-of-principle study in mice and rats; the text does not report human transplantation or long-term human safety, so clinical applicability remains unproven (evident from the models used).
  • The paper shows vascular connection “in principle,” but also indicates that the system still requires additional research for stable large-scale transplantation, especially for acute liver failure scenarios (stated and evident from the discussion).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/sciadv.ado1550

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. 3D-DLS gel exhibits ideal mechanical and 3D printing performance. (A) Schematic outline of the preparation of the 3D-DLS gel. (B) Extrusion of the 3D-DLS gel at different concentrations (1, 3, 5, and 7%) through a 27G needle. (C) 3D printing of liver scaffolds with a grid-like structure using different concentrations of the 3D-DLS gel (1, 3, 5, and 7%). (D) SEM images of liver scaffolds printed with 5% 3D-DLS gel. Scale bar, 10 μm. (E) Young’s modulus of the liver scaffolds and 8-week-old C57 mouse liver printed with grids of different concentrations/materials. (F) Viscosity and shear-thinning behavior of the 3D-DLS gel at different concentrations (3, 5, and 7%). (G) Compression representative curves of the 3D-DLS gel at different concentrations (3, 5, and 7%). (H) Storage (G′) and loss (G″) moduli of the 3D-DLS gel as a function of the applied oscillatory strain. Premade 10% 3D-DLS comprising 10% (w/v) LDCM, 10% (w/v) gelatin, and 2% (w/v) sodium alginate, 3D-DLS with concentrations of 1, 3, 5, and 7% were prepared by diluting 10% 3D-DLS with PBS. ns, not significant. ***P < 0.001.
Fig. 1. 3D-DLS gel exhibits ideal mechanical and 3D printing performance. (A) Schematic outline of the preparation of the 3D-DLS gel. (B) Extrusion of the 3D-DLS gel at different concentrations (1, 3, 5, and 7%) through a 27G needle. (C) 3D printing of liver scaffolds with a grid-like structure using different concentrations of the 3D-DLS gel (1, 3, 5, and 7%). (D) SEM images of liver scaffolds printed with 5% 3D-DLS gel. Scale bar, 10 μm. (E) Young’s modulus of the liver scaffolds and 8-week-old C57 mouse liver printed with grids of different concentrations/materials. (F) Viscosity and shear-thinning behavior of the 3D-DLS gel at different concentrations (3, 5, and 7%). (G) Compression representative curves of the 3D-DLS gel at different concentrations (3, 5, and 7%). (H) Storage (G′) and loss (G″) moduli of the 3D-DLS gel as a function of the applied oscillatory strain. Premade 10% 3D-DLS comprising 10% (w/v) LDCM, 10% (w/v) gelatin, and 2% (w/v) sodium alginate, 3D-DLS with concentrations of 1, 3, 5, and 7% were prepared by diluting 10% 3D-DLS with PBS. ns, not significant. ***P < 0.001.CC BY · PubMed Central
Fig. 2. In vitro cultivation using HEM culture medium enables the expansion of mice hepatocytes with both proliferative capacity and mature liver functionality. (A) Isolation of primary mice hepatocytes achieved through the perfusion method. (B) Images of cultured eHep cells at 15 passages in the HEM. Scale bar, 100 μm. NES, normalized enrichment score. (C) Growth curves of cultured eHep cells under the HEM. (D) Transcriptomic analyses of cell cycle–related genes. Freshly isolated mice hepatocytes and eHep cells were used for mRNA microarray analyses. (E) Expression of liver-related genes in mice fibroblasts (Fibro.), freshly isolated mice primary hepatocytes (PH), and eHep cells (eHep, P10) measured by quantitative polymerase chain reaction (qPCR). (F) Expression of ALBUMIN in eHep cells determined by immunofluorescent staining. The percentages of ALBUMIN-positive cells were quantified. Scale bar, 100 μm. (G) Glycogen storage in eHep cells at P10 analyzed by periodic acid–Schiff (PAS) staining. Scale bar, 200 μm. (H) Intake of ac-LDL in eHep cells (red staining). Scale bar, 200 mm. ***P < 0.001.
Fig. 2. In vitro cultivation using HEM culture medium enables the expansion of mice hepatocytes with both proliferative capacity and mature liver functionality. (A) Isolation of primary mice hepatocytes achieved through the perfusion method. (B) Images of cultured eHep cells at 15 passages in the HEM. Scale bar, 100 μm. NES, normalized enrichment score. (C) Growth curves of cultured eHep cells under the HEM. (D) Transcriptomic analyses of cell cycle–related genes. Freshly isolated mice hepatocytes and eHep cells were used for mRNA microarray analyses. (E) Expression of liver-related genes in mice fibroblasts (Fibro.), freshly isolated mice primary hepatocytes (PH), and eHep cells (eHep, P10) measured by quantitative polymerase chain reaction (qPCR). (F) Expression of ALBUMIN in eHep cells determined by immunofluorescent staining. The percentages of ALBUMIN-positive cells were quantified. Scale bar, 100 μm. (G) Glycogen storage in eHep cells at P10 analyzed by periodic acid–Schiff (PAS) staining. Scale bar, 200 μm. (H) Intake of ac-LDL in eHep cells (red staining). Scale bar, 200 mm. ***P < 0.001.CC BY · PubMed Central
Fig. 3. 3D-DLS gel demonstrates exceptional biocompatibility and facilitates the sustained proliferation of eHep cells. (A) Representative live-dead staining images of 3DP-liver structures at day 5 using different 3D-DLS concentrations. Live and dead cells were labelled with calcein-AM (green) and PI (red), respectively. Scale bar, 500 μm. (B) Assessment of eHep cells viability within the printed structures on day 5. Different concentrations of the 3D-DLS gel were used. (C) Representative optical images of 3DP-liver (using 5% 3D-DLS gel) at days 0, 2, 4, and 6. For better visualization, eHep-RFP cells were used. Scale bar, 5 mm. (D) Mean fluorescence intensity of eHep-RFP cells in 3DP-liver (using 5% 3D-DLS gel) at days 0, 2, 4, and 6. (E) Growth curves of eHep-RFP cells analyzed at different concentrations of 3D-DLS gel (3, 5, and 7%). (F) Proliferation of eHep cells assessed by Ki67 immunofluorescent staining on day 5. The percentages of Ki67-positive cells were quantified. Scale bar, 200 μm. DAPI, 4′,6-diamidino-2-phenylindole. (G) SEM images of 3DP-liver with 5% 3D-DLS gel. Scale bar, 15 μm (H) H&E staining of formalin-fixed paraffin-embedded 3DP-liver sections. Scale bar, 50 μm. ***P < 0.001.
Fig. 3. 3D-DLS gel demonstrates exceptional biocompatibility and facilitates the sustained proliferation of eHep cells. (A) Representative live-dead staining images of 3DP-liver structures at day 5 using different 3D-DLS concentrations. Live and dead cells were labelled with calcein-AM (green) and PI (red), respectively. Scale bar, 500 μm. (B) Assessment of eHep cells viability within the printed structures on day 5. Different concentrations of the 3D-DLS gel were used. (C) Representative optical images of 3DP-liver (using 5% 3D-DLS gel) at days 0, 2, 4, and 6. For better visualization, eHep-RFP cells were used. Scale bar, 5 mm. (D) Mean fluorescence intensity of eHep-RFP cells in 3DP-liver (using 5% 3D-DLS gel) at days 0, 2, 4, and 6. (E) Growth curves of eHep-RFP cells analyzed at different concentrations of 3D-DLS gel (3, 5, and 7%). (F) Proliferation of eHep cells assessed by Ki67 immunofluorescent staining on day 5. The percentages of Ki67-positive cells were quantified. Scale bar, 200 μm. DAPI, 4′,6-diamidino-2-phenylindole. (G) SEM images of 3DP-liver with 5% 3D-DLS gel. Scale bar, 15 μm (H) H&E staining of formalin-fixed paraffin-embedded 3DP-liver sections. Scale bar, 50 μm. ***P < 0.001.CC BY · PubMed Central
Fig. 4. 3DP-liver exhibit liver functions in vitro. (A) qPCR analysis of the expression of the hepatic marker gene expression in 2D-culture (2D), Matrigel-based 3D culture (Matrigel), freshly isolated mice primary hepatocytes (PH), and 3DP-liver (3D) after 5 days of in vitro culturing. (B) Expression of ALBUMIN and Zo1 in 3D-livers determined by coimmunofluorescent staining. Scale bar, 200 μm. (C) KEGG pathway analyses of the 933 genes that were specifically up-regulated in 3DP-liver. (D) mRNA levels of uninduced CYP and induced CYP enzymes determined by qPCR. Tail-tip fibroblasts (TTF); 2D-cultured (2D); Matrigel-based 3D culture (matrigel); 3DP-liver (3D); Cyp1a2 was induced by 3-methylcholanthrene. Cyp3a11 was induced by rifampicin. Cyp2e1 was induced by rifampicin and ethyl alcohol. DMSO, dimethyl sulfoxide. (E) P450-Glo assay of cytochrome activity (CYP1A2) in 3DP-liver after 5 days of in vitro culturing. (F) ICG uptake and release in 3DP-liver (green). Scale bar, 100 μm. (G) Glycogen storage determined by PAS staining. Scale bar, 50 μm. (H) Intake of ac-LDL (red staining) in 3DP-liverand print containing TTF (Fibro.). Scale bar, 200 μm. *P < 0.05 and ***P < 0.001.
Fig. 4. 3DP-liver exhibit liver functions in vitro. (A) qPCR analysis of the expression of the hepatic marker gene expression in 2D-culture (2D), Matrigel-based 3D culture (Matrigel), freshly isolated mice primary hepatocytes (PH), and 3DP-liver (3D) after 5 days of in vitro culturing. (B) Expression of ALBUMIN and Zo1 in 3D-livers determined by coimmunofluorescent staining. Scale bar, 200 μm. (C) KEGG pathway analyses of the 933 genes that were specifically up-regulated in 3DP-liver. (D) mRNA levels of uninduced CYP and induced CYP enzymes determined by qPCR. Tail-tip fibroblasts (TTF); 2D-cultured (2D); Matrigel-based 3D culture (matrigel); 3DP-liver (3D); Cyp1a2 was induced by 3-methylcholanthrene. Cyp3a11 was induced by rifampicin. Cyp2e1 was induced by rifampicin and ethyl alcohol. DMSO, dimethyl sulfoxide. (E) P450-Glo assay of cytochrome activity (CYP1A2) in 3DP-liver after 5 days of in vitro culturing. (F) ICG uptake and release in 3DP-liver (green). Scale bar, 100 μm. (G) Glycogen storage determined by PAS staining. Scale bar, 50 μm. (H) Intake of ac-LDL (red staining) in 3DP-liverand print containing TTF (Fibro.). Scale bar, 200 μm. *P < 0.05 and ***P < 0.001.CC BY · PubMed Central
Fig. 5. 3DP-liver transplantation rescues liver failure mice. (A) Macroscopic observation of the 3DP-liver transplantation after 1 week. Intravenous injection of FID reveals the vascular system after 10 min. Red, eHep-RFP cells; green, FID. Scale bar, 5 mm. (B) Schematic outline of 3DP-liver transplanted into the mesentery of Tek-Cre, Ai47-GFP mice. (C) Vascularization of 3DP-liver transplanted into the mesentery of Tek-Cre, Ai47-GFP mice after 7 days. Scale bar, 5 mm. (D) Immunofluorescence staining of CD31 in 3DP-livers 7 days after transplantation into C57 mice. Scale bar, 100 μm. (E) Schematic outline of the pathogenesis of Fah−/− mice. SA, succinylacetone; SAA, succinylacetoacetate. (F) Schematic outline of 3DP-liver transplanted into the mesentery of Fah−/− mice. (G) Survival curve of Fah−/− mice with 3DP-liver transplanted (3DP-liver, n = 8) and control Fah−/− mice (Fah−/−, n = 8) after NTBC withdrawal. (H) Body weight of Fah−/− mice (n = 8) and control Fah−/− mice (n = 8) measured after NTBC withdrawal. (I) Serum levels of TYR (tyrosine) and PHE (phenylalanine) in wild-type (WT, n = 3), Fah−/− mice (Fah−/−, n = 3), and Fah−/− mice with 3DP-liver transplanted (3DP-liver, n = 3, sera collected at 3 weeks after transplantation). (J) Serum levels of ALT, AST, ALB, TBA, TBIL, DBIL, and ALP in WT (n = 3), Fah−/− mice (n = 3), and Fah−/− mice with 3DP-liver transplanted (n = 3, sera collected at 3 weeks after transplantation). (K) H&E staining of liver from WT, Fah−/− mice, and Fah−/− mice with 3DP-liver transplanted. Scale bar, 100 μm. (L) Immunofluorescence costaining of ALBUMIN and FAH in 3DP-livers 1 month after transplantation into C57 mice and Fah−/− mice. Scale bar, 50 μm. **P < 0.01 and ***P < 0.001.
Fig. 5. 3DP-liver transplantation rescues liver failure mice. (A) Macroscopic observation of the 3DP-liver transplantation after 1 week. Intravenous injection of FID reveals the vascular system after 10 min. Red, eHep-RFP cells; green, FID. Scale bar, 5 mm. (B) Schematic outline of 3DP-liver transplanted into the mesentery of Tek-Cre, Ai47-GFP mice. (C) Vascularization of 3DP-liver transplanted into the mesentery of Tek-Cre, Ai47-GFP mice after 7 days. Scale bar, 5 mm. (D) Immunofluorescence staining of CD31 in 3DP-livers 7 days after transplantation into C57 mice. Scale bar, 100 μm. (E) Schematic outline of the pathogenesis of Fah−/− mice. SA, succinylacetone; SAA, succinylacetoacetate. (F) Schematic outline of 3DP-liver transplanted into the mesentery of Fah−/− mice. (G) Survival curve of Fah−/− mice with 3DP-liver transplanted (3DP-liver, n = 8) and control Fah−/− mice (Fah−/−, n = 8) after NTBC withdrawal. (H) Body weight of Fah−/− mice (n = 8) and control Fah−/− mice (n = 8) measured after NTBC withdrawal. (I) Serum levels of TYR (tyrosine) and PHE (phenylalanine) in wild-type (WT, n = 3), Fah−/− mice (Fah−/−, n = 3), and Fah−/− mice with 3DP-liver transplanted (3DP-liver, n = 3, sera collected at 3 weeks after transplantation). (J) Serum levels of ALT, AST, ALB, TBA, TBIL, DBIL, and ALP in WT (n = 3), Fah−/− mice (n = 3), and Fah−/− mice with 3DP-liver transplanted (n = 3, sera collected at 3 weeks after transplantation). (K) H&E staining of liver from WT, Fah−/− mice, and Fah−/− mice with 3DP-liver transplanted. Scale bar, 100 μm. (L) Immunofluorescence costaining of ALBUMIN and FAH in 3DP-livers 1 month after transplantation into C57 mice and Fah−/− mice. Scale bar, 50 μm. **P < 0.01 and ***P < 0.001.CC BY · PubMed Central
Fig. 6. Transplantation of 3DP-liver with artificial blood vessels. (A) Schematic outline of the preparation of 3DP-liver with artificial blood vessels. (B) Representative optical images of 3DP-liver with artificial blood vessels. For better visualization, eHep-RFP cells and HUVEC-GFP were used. Scale bar, 5 mm. (C) Diffusion of Cy7 fluorescent dye within 3DP-liver with artificial blood vessels. Scale bar, 5 mm. (D) Mean fluorescence intensity at various time points in different regions of the 3DP-liver after perfusion with Cy7 fluorescent dye. (E) Glucose concentration in PBS after perfusion with glucose via artificial blood vessels. (F) Surgical anastomosis of the 3DP-liver with artificial blood vessels in rat was performed through the inferior vena cava and portal vein. Blood perfusion was established immediately after anastomosis. Scale bar, 1 cm.
Fig. 6. Transplantation of 3DP-liver with artificial blood vessels. (A) Schematic outline of the preparation of 3DP-liver with artificial blood vessels. (B) Representative optical images of 3DP-liver with artificial blood vessels. For better visualization, eHep-RFP cells and HUVEC-GFP were used. Scale bar, 5 mm. (C) Diffusion of Cy7 fluorescent dye within 3DP-liver with artificial blood vessels. Scale bar, 5 mm. (D) Mean fluorescence intensity at various time points in different regions of the 3DP-liver after perfusion with Cy7 fluorescent dye. (E) Glucose concentration in PBS after perfusion with glucose via artificial blood vessels. (F) Surgical anastomosis of the 3DP-liver with artificial blood vessels in rat was performed through the inferior vena cava and portal vein. Blood perfusion was established immediately after anastomosis. Scale bar, 1 cm.CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 1 Not valid · 6 Not checked · 93 Own results and interpretations

73 more claims

Create a free account to see all 102 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 18
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 47

Metadata

Authors
Deng, B., Ma, Y., Huang, J., He, R., Luo, M., Mao, L., Zhang, E., Zhao, Y., Wang, X., Wang, Q., Pang, M., Mao, Y., Yang, H., Liu, L., & Huang, P.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Jiangxi Maternal and Child Health Hospital (CN)
Corresponding author
  • Deng, Bo
  • Ma, Yue
  • Huang, Jialyu
  • Yang, Huayu
  • Liu, Lanxia
  • Huang, Pengyu
Venue
Science Advances
Published
2024-06-07
Volume
10
Issue
23
Pages
eado1550-eado1550
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4399425544
Cited by
47
References
36
Citations by year
2026: 26 · 2025: 19 · 2024: 2
FWCI
5.14
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
3D bioprinting, bioartificial liver, liver failure, primary hepatocytes, hepatocyte expansion, bioinks, heterotopic transplantation, tyrosinemia, artificial blood vessels, vascular integration, liver regeneration
MeSH terms
Animals, Disease Models, Animal, Liver, Liver Transplantation, Liver Failure, Liver, Artificial, Tyrosinemias, Hepatocytes, Tissue Engineering, Mice, Tissue Scaffolds, Bioprinting, Printing, Three-Dimensional

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.